Increased Incidence of Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia Among Adults of Hispanic Ethnicity: A Population Based Study

Abstract Introduction: Previous population-based studies in pediatric acute lymphoid leukemia (ALL) have identified racial and ethnic differences in incident childhood ALL (Med Pediatr Oncol 2002;39:554), but the degree to which these disparities persist among adult ALL patients, who have distinct differences in the molecular subtypes of ALL compared to children, is less clear. Larger studies that look across broad populations of patients are needed to assess these findings in adult ALL. We therefore used the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database to characterize the incidence of distinct subtypes of ALL in adults, to evaluate whether differences in racial or ethnic incidence rates are seen in the adult population and relate to molecular subtypes of disease. Methods: The 1973-2014 SEER-18 database was used to identify adults, age 20 years or older, diagnosed with lymphoid leukemia between 2000 and 2014. We included only patients with documented race/ethnicity and known age at diagnosis. Leukemia subtypes were defined by the third edition of the Internal Classification of Diseases for Oncology (ICD-O-3) and stratified by cell lineage and BCR-ABL mutation status. BCR-ABL mutation status was added to SEER in 2010 so analysis of these subgroups includes only patients diagnosed 2010-2014. Analysis was carried out comparing ethnicity, Hispanic (H) vs. non- Hispanic (NH), as well as race/ethnicity, non-Hispanic White (NHW) vs. Hispanic White (HW), non-Hispanic Black (NHB) or non-Hispanic Asian-Pacific Islander (NHAPI). Age-adjusted incidence rates (IRs) per 100,000 person-years were calculated using the Rate Session in SEER*Stat. Incidence rate ratios (IRR) were calculated using STATA software. Two-sided p-values were calculated using the mid-p test. Results: An overall higher incidence of ALL was present among patients of Hispanic ethnicity as compared to non-Hispanic (IR 1.59 vs. 1.08, IRR 1.47 p Conclusions: In children, published data suggests an overall increased incidence of ALL among patients of Hispanic ethnicity and a decreased incidence among patients of Black race. Our analysis of SEER data from 2000-2014 shows that these patterns persist among adult patients. Interestingly, in this large, population-based study, we found that the higher rates of ALL among Hispanic populations are largely related to a higher incidence of Ph-negative B-cell ALL, a pattern that persists across all ages (figure 1). We also found an overall decreased rate among NHB patients, despite an increase in T-cell ALL. This is also consistent with findings seen in childhood ALL. The specific trends with Ph-negative B-cell ALL have not been previously described, likely due to limited availability of molecular data until this point. In this study, we found no difference in incidence rates of Ph-positive ALL in Hispanic vs. non-Hispanic populations across all age groupings. Our findings suggest that some underlying mechanism may contribute to higher rates of Ph-negative ALL in this population. Previously hypothesized explanations for this difference include susceptibility genes (ARID5B, PIP4K2A) which may be enriched in certain populations, environmental toxins or chemicals, viruses or other environmental factors. Whether some or most of these factors would account for the approximately double incidence of Ph-negative B-cell ALL across all ages remains unclear and requires further study. Download : Download high-res image (163KB) Download : Download full-size image Disclosures Fathi: Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Medimmune: Consultancy, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Juno: Membership on an entity's Board of Directors or advisory committees; Takeda: Research Funding; Pfizer: Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Brunner: Celgene: Research Funding; Takeda: Research Funding.